biOOrg3.14

biOOrg3.14 is advancing a portfolio of programs in oncology, diabetes, anti-pathogen therapeutics, and retinal disease.

Each program was selected based on three criteria:

Significant unmet medical need.

A differentiated therapeutic approach.

The ability to generate early clinical proof-of-concept to unlock substantial value before commercialization.

By advancing differentiated programs that can be derisked early in clinical testing, biOOrg3.14 aims to create opportunities for rapid valuation growth, strategic partnerships, and transactions.

Click below to learn about each of our therapeutic innovations, their potential impacts, and clinical status:

DIABETES

A DISEASE-MODIFYING SHORT-COURSE THERAPY FOR DIABETES REMISSION

ONCOLOGY

A DUAL CYTOTOXIC AND IMMUNOMODULATOR FOR HEPATOCELLULAR CARCINOMA

PATHOGENS

A PAN-ANTIVIRAL, -BACTERIAL, -FUNGAL, AND -PROTOZOAL THERAPY

OPHTHALMOLOGY

AN ORAL THERAPY FOR STARGARDT DISEASE AND GEOGRAPHIC ATROPHY

All drug candidates are investigational and not approved for commercial use.

For more information about the strategy behind our programs:

EMAIL US

FOUNDED IN 2017

SITEMAP
PRIVACY POLICY
TERMS OF USE